ALK and neuroblastoma: However, the majority of the tumors that harbor the crizotinib- and ceritinib-sensitive ALK R1275Q mutation did not respond in the trials of crizotinib and ceritinib in neuroblastoma patients (Mossé et al., 2013; Birgit Geoerger et al., 2015).